United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Company Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Wednesday, October 7th. The shares were sold at an average price of $548.95, for a total value of $5,215,025.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $178,102,984.85. This trade represents a 2.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

United Therapeutics Trading Down 2.2%

Shares of NASDAQ UTHR traded down $12.22 during trading on Thursday, reaching $532.78. The company had a trading volume of 1,435,280 shares, compared to its average volume of 553,496. United Therapeutics Corporation has a twelve month low of $409.07 and a twelve month high of $609.35. The stock has a 50-day moving average price of $511.23 and a two-hundred day moving average price of $539.87. The stock has a market capitalization of $22.85 billion, a PE ratio of 19.06, a price-to-earnings-growth ratio of 2.72 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same quarter last year, the company earned $6.41 earnings per share. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.21 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Toth Financial Advisory Corp boosted its holdings in shares of United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares during the last quarter. Fiduciary Financial Advisors acquired a new stake in shares of United Therapeutics during the 2nd quarter worth $30,000. Caitlin John LLC purchased a new position in shares of United Therapeutics in the 2nd quarter worth $37,000. International Assets Investment Management LLC boosted its holdings in United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 64 shares during the last quarter. Finally, Keating Financial Advisory Services Inc. acquired a new position in United Therapeutics in the second quarter valued at $81,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of United Therapeutics in a research report on Thursday, October 1st. Royal Bank Of Canada increased their price target on United Therapeutics from $677.00 to $708.00 and gave the stock an “outperform” rating in a research note on Thursday. Bank of America decreased their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. The Goldman Sachs Group assumed coverage on United Therapeutics in a research report on Thursday, September 24th. They issued a “sell” rating and a $321.00 price objective for the company. Finally, Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $627.31.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.